Colin Hale

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani et al. · The Lancet Infectious Diseases · 2022 · 177 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings et al. · Journal of Antimicrobial Chemotherapy · 2021 · 118 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Slug initiation and evolution in two-phase horizontal flow

Priscilla Midah Ujang, C.J. Lawrence, Colin Hale et al. · International Journal of Multiphase Flow · 2006 · 110 citations

Engineering, Physics, Fluid Dynamics +13

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva

Alieu Amara, Sujan Dilly Penchala, Laura Else et al. · Journal of Pharmaceutical and Biomedical Analysis · 2021 · 82 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders et al. · The Lancet Infectious Diseases · 2022 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14